Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks.com
Acrivon Therapeutics reports 62.5% response rate for ACR-368 in endometrial cancer patients, with no median duration reached at 6 months. FDA clears ACR-2316 for Phase 1 trials, starting Q4 2024. Company has funds until H2 2026, driven by AP3 Interactome platform.
Reference News
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks.com
Acrivon Therapeutics reports 62.5% response rate for ACR-368 in endometrial cancer patients, with no median duration reached at 6 months. FDA clears ACR-2316 for Phase 1 trials, starting Q4 2024. Company has funds until H2 2026, driven by AP3 Interactome platform.